Topical delivery of active principles: The field of dermatological research

Dermatology Online Journal

Volumn 16, Issue 1, 2010, Pages

  Nino, Massimiliano ^a   Calabrò, Gabriella ^a   Santoianni, Pietro ^a  

^a Section of Dermatology ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ALCOHOL; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; CLONIDINE; CORTICOSTEROID; DERMATOLOGICAL AGENT; DEXAMETHASONE; DIMETHYL SULFOXIDE; GLYCERYL TRINITRATE; KHELLIN; LIDOCAINE; METHYLPREDNISOLONE; NICOTINIC ACID; PROPYLENE GLYCOL; SCOPOLAMINE; DRUG VEHICLE; EXCIPIENT; LIPOSOME;

DERMATOLOGY; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG PENETRATION; ELECTROPORATION; HUMAN; INTRADERMAL DRUG ADMINISTRATION; IONTOPHORESIS; LASER; MEDICAL RESEARCH; REVIEW; STRATUM CORNEUM; THERAPY EFFECT; TOPICAL TREATMENT; VITILIGO; BIOAVAILABILITY; DRUG EFFECT; LOW LEVEL LASER THERAPY; SKIN; SKIN ABSORPTION; TOPICAL DRUG ADMINISTRATION; ULTRASOUND; VEHICLES;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, TOPICAL; BIOLOGICAL AVAILABILITY; DERMATOLOGIC AGENTS; ELECTROPORATION; EXCIPIENTS; HUMANS; INJECTIONS, INTRADERMAL; IONTOPHORESIS; LASER THERAPY, LOW-LEVEL; LIPOSOMES; PHONOPHORESIS; SKIN; SKIN ABSORPTION; VEHICLES;

EID: 75749124248     PISSN: None     EISSN: 10872108     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Dermatological and Transdermal Formulations. Marcel Dekker, Inc. New York 2002
2. Bronaugh RL, Maibach HI. Percutaneous Absorption: Drugs -Cosmetics - Mechanisms - Methodology (Drugs and the Pharmaceutical Sciences). Informa Healthcare; 4th Ed., 2005.
3. Smith EW, Maibach HI. Penetration percutaneous enhancers. Taylor and Francis, 2nd Ed, 2006.
4. Lampe MA, Burlingame AL, Whitney J, Williams ML, Brown BE, Roitman E. Human stratum corneum lipids: characterization and regional differences. J Lipid Res 1983; 24: 120-30.
5. Elias PM, Menon GK. Structural and lipid biochemical correlates of the epidermal permeability barrier. Adv Lipid Res 1991; 24: 1-26. [PubMed]
6. Elias PM, Tsai JC, Menon GK. Skin barrier, percutaneous drug delivery and pharmacokinetics. Dermatology, 2003. Chap 125, p 1235-52.Mosby, editor.
7. Elias PM, Feingold KR, Menon JK. The stratum corneum, two compartments model and its functional implication. In Basel, Karger Shroot B, Shaefer H, editors. Skin Pharmacokinetics 1987. vol.1. p 1-9.
8. Surber C, Davis AF. Bioavailability and Bioequivalence of Dermatological Formulations p401-498. in: Dermatological and Transdermal Formulations.vol 119. Marcel Dekker, Inc. New York 2002.
9. Roberts MS, Cross SE, Pellett MA. Skin transport p 89-195 in: Dermatological and Transdermal Formulations.vol 119. Marcel Dekker, Inc. New York 2002.
10. Menon GK, Elias PM. Morphologic basis for a pore-pathway in mammalian stratum corneum. Skin Pharmacol 1997;10:235-46. [PubMed]
11. Watkinson AC, Brain KR. Basic mathematical principles in skin permeation p 61-88: in Dermatological and Transdermal Formulations.vol 119. Marcel Dekker, Inc. New York.
12. Franz TJ. Kinetics of cutaneous drug penetration. Int J Dermatol 1983; 499-505. [PubMed]
13. Franz TJ. Pharmacokinetics and skin in: Skin barrier, percutaneous drug delivery and pharmacokinetics. p 1969-78 in Dermatology,vol II. Mosby, 2003.
14. Orecchia G, Sangalli ME, Gazzaniga A, et al. Topical photochemotherapy of vitiligo with a new khellin formulation: preliminary clinical results. J Dermatol Treat 1998; 9: 65-9.
15. Roberts M, Cross SE, Pellett MA. Skin transport in Dermatological and Transdermal Formulations.vol 119. Marcel Dekker, Inc. New York 2002.
16. Middleton JD. The mechanism of water binding in stratum corneum. Br J Dermatol 1968; 80:437-50
17. Horii I, Nakajama Y, Obate Ml. Stratum corneum hydration and aminoacids contant in xerotic skin. Br J Dermatol Res 1989; 121: 588-64.
18. Imokawa G, Kuno H, Kawai M. Stratum corneum lipids serve as bound-water modulator. J Invest Dermatol 1991; 96: 845-51. [PubMed]
19. Mauro T, Hollerann WM, Grayson S, Gao WN, Man MQ, Kriehuber E, et al. Barrier recovery is impeded at neutal pH, independent of ionic effects: implications for extracellular lipid processing. Arch Dermatol Res 1998; 290: 215-22. [PubMed]
20. Rougier A, Lotte C, Corcuff TP. Relationship between skin permeability and cornecyte size according to anatomic site, age and sex in man. J Soc Cosmet Chem 1988; 39: 15-21. [PubMed]
21. Berardesca E, Maibach HI. Racial differences in skin pathophysiology. J Am Acad Dermatol 1996; 34: 667-72. [PubMed]
22. Menon GK, Elias PM, Feingold KR. Integrity of the permeability barrier is crucial for manteinance of the epidermal calcium gradient. Br J Dermatol 1994; 130: 139-47.
23. Surber C, Davis AF. Bioavailability and Bioequivalence of Dermatological Formulations p401-498. in: Dermatological and Transdermal Formulations.vol 119. Marcel Dekker,Inc. New York 2002. [PubMed]
24. Hauck WW. Bioequivalence studies of topical preparations: statistical considerations. Int J Dermatol 1992; 31 (suppl. 1): 29-33.
25. Skelly JP, Shah VP, Maibach HI. FDA and AAPS report of workshop on principles and practices of in vitro percutaneous penetration studies: relevance to bioavailability and bioequivalence. Pharm Res 1987; 4: 265-71.
26. Shah VP, Elkins J, Hanus J, Noorizadeh C, Skelly JP. In vitro release fo hydrocortisone from topical preparations and automated procedure. Pharm Res 1991; 8: 55-9.
27. Davis AF, Gyurik RJ, Hadgraft J. Formulation strategies for modulating skin permeation in Dermatological and Transdermal Formulations.vol 119. Marcel Dekker, Inc. New York 2002. [PubMed]
28. Patil S, Singh P, Szolar-Platzer C, Maibach HI. Epidermal enzymes as penetration enhancers in transdermal drug delivery? J Pharm Sci 1996; 85: 249-52.
29. Mitragotri S. Synergistic effects of enhancers for transdermal drug delivery. Pharm Res 2000; 17: 1354-9. [PubMed]
30. Tsai JC, Guy RH, Thornfeldt CR, Gao WN, Feingold KR, Elias PM. Metabolic approaches to enhance transdermal drug delivery. 1. Effect of lipid synthesis inhibitors. J Pharm Sci 1996; 85: 643-8. [PubMed]
31. Johnson ME, Mitragotri S, Patel A, Blankschtein D, Langer R. Synergistic effects of chemical enhancers and therapeutic ultrasounds on transdermal drug delivery. J Pharm Sci 1996; 85: 670-9. [PubMed]
32. Choi EH, Lee SH, Ahn SK, Hwang SM. The pretreatment effect of chemical skin penetration enhancers in transdermal drug delivery. Skin Pharmacol Appl Skin Physiol 1999; 12: 326-35.
33. Singh J, Maibach HI. Transdermal delivery and cutaneous reactions. in: Dermatological and Transdermal Formulations.vol 119. Marcel Dekker, Inc. New York 2002.
34. Korting HC, Stolz W, Schmid MH, Maierhofer G. Interaction of liposomes with human epidermis reconstructed in vitro. Br J Dermatol 1995; 132: 571-9. [PubMed]
35. Kassan DG Lynch AM, Stiller MJ. Physical enhancement of dermatologic drug delivery: iontophoresis and phonophoresis. J Am Acad Dermatol 1996; 34: 657-66. [PubMed]
36. Ka-yun Ng, Yang Liu. Therapeutic ultrasound: its application in drug delivery. Medicinal Research reviews 2002; 22: 204-8.
37. Merino G, Kalia YN, Guy RH. Ultrasound-enhanced transdermal transport. J Pharm Sci 2003, 92: 1125-37. [PubMed]
38. Bommannan D, Menon GK, Okuyama H, et al. Sonophoresis. II. Examination of the mechanism(s) of ultrasound-enhanced transdermal drug delivery. Pharm Res1992;9:1043-48. [PubMed]
39. Santoianni P, Nino M, Calabro' G. Intradermal drug delivery by low-frequency sonophoresis (25 KHz). Dermatology Online Journal 2004; 10: 24-32. [PubMed]
40. Terahara T, Mitragotri S, Kost J, Langer R. Dependence of low-frequency sonophoresis on ultrasound parameters: distance of the horn and intensity. Int J Pharm 2002; 235: 35. [PubMed]
41. Tezel A, Sens A, Tuchscherer J, Mitragotri S. Frequency dependence of sonophoresis. Pharm Res 2001; 18: 1694-700. [PubMed]
42. Fang J, Fang C, Sung KC, Chen H. Effect of low frequency ultrasound on the in vitro percutaneous absorption of clobetasol 17-propionate. Int J Pharm 1999; 191:33-42. [PubMed]
43. Mitragotri S, Farrell J, Tang H. Determination of threshold energy dose for ultrasound-induced transdermal drug transport. J Control Release 2000; 63: 41-48. [PubMed]
44. Machet L, Cochelin N, Patat F. In vitro phonophoresis of mannitol, oestradiol and hydrocortisone across human and hairless mouse skin. Int J Pharm 1998; 165: 169-74. [PubMed]
45. Merino G, Kalia YN, Delgado-Charro MB, Potts RO, Guy RH. Frequency and thermal effects on the enhancement of transdermal transport by sonophoresis. J Control Release 2003; 88: 85-94. [PubMed]
46. Machet L, Boucaud A. Phonophoresis: efficiency, mechanisms and skin tolerance. Int J Pharm 2002; 243: 1-15. [PubMed]
47. Tang H, Wang CC, Blankschtein D, Langer R. An investigation of the role of cavitation in low-frequency ultrasound-mediated transdermal drug transport. Pharm Res 2002; 19: 1160-9. [PubMed]
48. Tezel A, Sens A, Mitragotri S. Description of transdermal transport of hydrophilic solutes during low-frequency sonophoresis based on a modified porous pathway model. J Pharm Sci 2003; 92: 381-93. [PubMed]
49. Wu J, Chappelow J, Yang J. Defects generated in human stratum corneum specimens by ultrasound. Ultrasound In Med. & Biol.1998, Vol. 24, No. 5, p. 705-12.
50. Le L, Kost J, Mitragotri S. Combined effect of low-frequency ultrasound and iontophoresis: applications for transdermal heparin delivery. Pharm Res 2000; 17: 1151-4. [PubMed]
51. Mitragotri S, Ray D, Farrell J, Tang H, Yu B, Kost J, et al. Synergistic effect of low-frequency ultrasound and sodium lauryl sulfate on transdermal transport. J Pharm Sci 2000; 89: 892-900. [PubMed]
52. Mitragotri S, Blankschtein D, Langer R. An explanation for the variation of the sonophoretic transdermal transport enhancement from drug to drug. J Pharm Sci 1997; 86: 1190-2. [PubMed]
53. Tachibana K, Tachibana S. Application of Ultrasound Energy as a New Drug Delivery System. Japanese J Appl Phys 1999. Vol. 38 Part 1, No. 5B p.3014-3019.
54. Singh S, Singh J. Transdermal drug delivery by passive diffusion and iontophoresis: a review. Med Res Rev 1993; 13: 569-621. [PubMed]
55. Holzle E, Alberti N. Long-term efficacy and side effects of tap water iontophoresis of palmoplantar hyperhidrosis. The usefulness of home therapy. Dermatologica1987;175:126-33. [PubMed]
56. Menon GK, Elias PM. Morphologic basis for a pore-pathway in mammalian stratum corneum. Skin Pharmacol 1997; 10: 235-46. [PubMed]
57. Santi P, Volpato NM Colombo P. Iontophoresis enhances the transport of acyclovir through nude mouse skin by electrorepulsion d elecroosmosis. Pharm Res 1995; 12: 1623-7. [PubMed]
58. Pikal MJ. The role of elecroosmotic flow in transdermal iontophoresis. Adv Drug Del Rev 2001; 46: 281-305. [PubMed]
59. Grewal BS, Naik A, Irwin WJ, Gooris G, de Grauw CJ, Gerritsen HG, et al. Transdermal macromolecular delivery: realtime visualization of iontophoretic and chemically enhanced transport using two-photon excitation microscopy. Pharm Res 2000; 17: 788-95. [PubMed]
60. Marconi B, Mancini F, Colombo P, Allegra F, Giordano F, Gazzaniga A, et al. Distribution of khellin in excised human skin following iontophoresis and passive dermal transport. J Control Rel 1999; 60: 261-8. [PubMed]
61. Brand RM, Wahl A, Iversen PL. Effects of size and sequence on the iontophoretic delivery of oligonucleotides. J Pharm Sci 1998; 87: 49. [PubMed]
62. Volpato NM, Nicoli S, Laureri C, Colombo P, Santi P. In vitro acyclovir distribution in human skin layers after transdermal iontophoresis. J Control Release 1998; 50: 291-6. [PubMed]
63. Gangarosa LP Sr, Ozawa A, Ohkido M, Shimomura Y, Hill JM. Iontophoresis for enhancing penetration of dermatologic and antiviral drugs.J Dermatol 1995; 22: 865-75. [PubMed]
64. Gangarosa LP, Hill JM. Modern iontophoresis for local drug delivery. Int J Pharm 1995; 123:159-66. [PubMed]
65. Banga AK, Chien YW. Hydrogel-based iontotherapeutic delivery devices for transdermal delivery of peptide/protein drugs. Pharm Res 1993; 10: 697-702. [PubMed]
66. Fang JY, Kuo CT, Fang CL. Transdermal iontophoresis of sodium nonivamide acetate evaluated by in vivo microdialysis and histologic study. Drug Development Research 1999; vol. 46, issue 2, 87.
67. Wolf SL. Electrotherapy, clinics in physical therapy. Churchill Livingstone, 1981.
68. Le L, Kost J, Mitragotri S. Combined effect of low-frequency ultrasound and iontophoresis: applications for transdermal heparin delivery. Pharm Res 2000; 17: 1151-4. [PubMed]
69. Potts RO. Transdermal peptide delivery using electroporation. In: Proceedings of the Thrid TDS Technology Symposium: polymers and peptides in transdermal delivery. 47-67, 1993.
70. Sharma A, Kara M, Smith FR, Krishnan TR.Transdermal drug delivery using electroporation. I. Factors influencing in vitro delivery of terazosin hydrochloride in hairless rats. J Pharm Sci 2000;89:528-35. [PubMed]
71. Sharma A, M. Kara M, Smith FR, Krishnan TR. Transdermal drug delivery using electroporation. II. Factors influencing skin reversibility in electroporative delivery of terazosin hydrochloride in hairless rats. J Pharm Sci 2000; 89: 536-44. [PubMed]
72. Aloisi A, M. Matera M, Potenza M. Cryoelectrophoresis: Painless administration of drugs through a suitable association of thermal and electrical techniques. G Ital Dermatol Venereol 2005; 151: 345-8.
73. Misefari M, D' Africa A, Sartori M, Morabito F. Transdermal transport by hydroelectrophoresis: a novel method for delivering molecules. J Biol Regul Homeost Agents 2001; 15: 381-4. [PubMed]
74. Makoto O, Shunichi S, Masahiko K, et al. Transdermal delivery of photosensitizer by the laser-induced stress wave in combination with skin heating. Japanese J Appl Phys 2002. Vol. 41 Part2, pp. L814.